| For: | Abdul-Baki H, El Hajj II, ElZahabi L, Azar C, Aoun E, Skoury A, Chaar H, Sharara AI. A randomized controlled trial of imipramine in patients with irritable bowel syndrome. World J Gastroenterol 2009; 15(29): 3636-3642 [PMID: 19653341 DOI: 10.3748/wjg.15.3636] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i29/3636.htm |
| Number | Citing Articles |
| 1 |
Taraneh Mousavi, Shekoufeh Nikfar, Mohammad Abdollahi. An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome. Expert Opinion on Drug Metabolism & Toxicology 2020; 16(7) doi: 10.1080/17425255.2020.1767067
|
| 2 |
|
| 3 |
. 2017; doi: 10.70675/7208205dzdc77z45a8z81b5ze082be4479d8
|
| 4 |
Anita Sainsbury, Alexander C. Ford. Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. Therapeutic Advances in Gastroenterology 2011; 4(2) doi: 10.1177/1756283X10387203
|
| 5 |
Johanne L Agger, Andreas Schröder, Lise K Gormsen, Jens S Jensen, Troels S Jensen, Per K Fink. Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study. The Lancet Psychiatry 2017; 4(5) doi: 10.1016/S2215-0366(17)30126-8
|
| 6 |
Sattar Jafari, Soudeh Khalili Mahani, Neda Mohsen-Pour. Comparison of the Effect of Duloxetine and Imipramine in the Treatment of Patients with Diarrhea Dominant Irritable Bowel Syndrome. Journal of Advances in Medical and Biomedical Research 2024; 32(150) doi: 10.61186/jambr.32.150.33
|
| 7 |
A. C. Ford, P. Moayyedi. Meta‐analysis: factors affecting placebo response rate in the irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 2010; 32(2) doi: 10.1111/j.1365-2036.2010.04328.x
|
| 8 |
Chen Xie, Yurong Tang, Yunfeng Wang, Ting Yu, Yun Wang, Liuqin Jiang, Lin Lin, Lin Lu. Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis. PLOS ONE 2015; 10(8) doi: 10.1371/journal.pone.0127815
|
| 9 |
Michelle Bosman, Sigrid Elsenbruch, Maura Corsetti, Jan Tack, Magnus Simrén, Bjorn Winkens, Thimo Boumans, Ad Masclee, Daniel Keszthelyi. The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 2021; 6(6) doi: 10.1016/S2468-1253(21)00023-6
|
| 10 |
Mais Khasawneh, Elyse R Thakur, Vivek C Goodoory, Paul Moayyedi, Christopher J Black, Alexander C Ford. Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut 2026; doi: 10.1136/gutjnl-2026-339311
|
| 11 |
Alexander C. Ford, Brian E. Lacy, Lucinda A. Harris, Eamonn M.M. Quigley, Paul Moayyedi. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. American Journal of Gastroenterology 2019; 114(1) doi: 10.1038/s41395-018-0222-5
|
| 12 |
H. Duboc, M. Dior, B. Coffin. Le syndrome de l’intestin irritable : nouvelles pistes physiopathologiques et conséquences pratiques. La Revue de Médecine Interne 2016; 37(8) doi: 10.1016/j.revmed.2015.12.030
|
| 13 |
Agnieszka Kułak-Bejda, Grzegorz Bejda, Napoleon Waszkiewicz. Antidepressants for irritable bowel syndrome—A systematic review. Pharmacological Reports 2017; 69(6) doi: 10.1016/j.pharep.2017.05.014
|
| 14 |
Alexander C. Ford, Paul Moayyedi, William D. Chey, Lucinda A. Harris, Brian E. Lacy, Yuri A. Saito, Eamonn M. M. Quigley. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. American Journal of Gastroenterology 2018; 113 doi: 10.1038/s41395-018-0084-x
|
| 15 |
Christopher J Black, Yuhong Yuan, Christian P Selinger, Michael Camilleri, Eamonn M M Quigley, Paul Moayyedi, Alexander C Ford. Efficacy of soluble fibre, antispasmodic drugs, and gut–brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. The Lancet Gastroenterology & Hepatology 2020; 5(2) doi: 10.1016/S2468-1253(19)30324-3
|
| 16 |
Ola Ghaith, Mustapha El-Halabi, Jana G Hashash, Ala I Sharara. Investigational agents for the irritable bowel syndrome. Expert Opinion on Investigational Drugs 2010; 19(10) doi: 10.1517/13543784.2010.513380
|
| 17 |
Reham Gendi, Nusrat Jahan. Pharmacological and Non-pharmacological Treatments of Irritable Bowel Syndrome and Their Impact on the Quality of Life: A Literature Review. Cureus 2020; doi: 10.7759/cureus.9324
|
| 18 |
T Mazzawi, T Hausken, D Gundersen, M El-Salhy. Effect of dietary management on the gastric endocrine cells in patients with irritable bowel syndrome. European Journal of Clinical Nutrition 2015; 69(4) doi: 10.1038/ejcn.2014.151
|
| 19 |
Tarek Mazzawi, Doris Gundersen, Trygve Hausken, Magdy El-Salhy. Increased Chromogranin A Cell Density in the Large Intestine of Patients with Irritable Bowel Syndrome after Receiving Dietary Guidance. Gastroenterology Research and Practice 2015; 2015 doi: 10.1155/2015/823897
|
| 20 |
Catherine C. Crone, Jeanne M. Lackamp, Andrew R. Alkis. The American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liaison Psychiatry. 2018; doi: 10.1176/appi.books.9781615371990.jl19
|
| 21 |
Ruben D Acosta, Brooks D Cash. Existing and emerging therapies for irritable bowel syndrome. Expert Opinion on Emerging Drugs 2011; 16(2) doi: 10.1517/14728214.2011.566214
|
| 22 |
Emanuele Sinagra, Claudia Romano, Mario Cottone. Psychopharmacological Treatment and Psychological Interventions in Irritable Bowel Syndrome. Gastroenterology Research and Practice 2012; 2012 doi: 10.1155/2012/486067
|
| 23 |
Sun Jung Oh, Will Takakura, Ali Rezaie. Shortcomings of Trials Assessing Antidepressants in the Management of Irritable Bowel Syndrome: A Critical Review. Journal of Clinical Medicine 2020; 9(9) doi: 10.3390/jcm9092933
|
| 24 |
Tarek Mazzawi, Magdy El-Salhy. Changes in duodenal enteroendocrine cells in patients with irritable bowel syndrome following dietary guidance. Experimental Biology and Medicine 2017; 242(13) doi: 10.1177/1535370217699537
|
| 25 |
Jalal Doufik, Omar El Oumary, Zineb Salehddine, Mina Ouhamou, Hicham Laaraj, Khalid Mouhadi, Ismail Rammouz. La place des antidépresseurs dans le syndrome du côlon irritable : Le point sur la littérature. Annales Médico-psychologiques, revue psychiatrique 2025; 183(2) doi: 10.1016/j.amp.2024.11.012
|
| 26 |
Mais Khasawneh, Marjan Mokhtare, Paul Moayyedi, Christopher J Black, Alexander C Ford. Efficacy of gut–brain neuromodulators in irritable bowel syndrome: an updated systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 2025; 10(6) doi: 10.1016/S2468-1253(25)00051-2
|
| 27 |
Jonathan A. Busam, Nisha Batta, Eric D. Shah, LiJin Joo, Caroline Marshall, Ali Rezaie, Mark Pimentel. The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology 2026; 121(3) doi: 10.14309/ajg.0000000000003572
|
| 28 |
Lisa Ruepert, A Otto Quartero, Niek J de Wit, Geert J van der Heijden, Gregory Rubin, Jean WM Muris. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2011; 2013(3) doi: 10.1002/14651858.CD003460.pub3
|
| 29 |
Magdy El-Salhy. Recent advances in the diagnosis of irritable bowel syndrome. Expert Review of Gastroenterology & Hepatology 2015; 9(9) doi: 10.1586/17474124.2015.1067138
|
| 30 |
Esther Colomier, Joost Algera, Chloé Melchior. Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea. Frontiers in Pharmacology 2021; 11 doi: 10.3389/fphar.2020.629026
|
| 31 |
Tarek Mazzawi, Magdy El-Salhy. Dietary guidance and ileal enteroendocrine cells in patients with irritable bowel syndrome. Experimental and Therapeutic Medicine 2016; 12(3) doi: 10.3892/etm.2016.3491
|
| 32 |
Alexander C Ford, Paul Moayyedi, Brian E Lacy, Anthony J Lembo, Yuri A Saito, Lawrence R Schiller, Edy E Soffer, Brennan M R Spiegel, Eamonn M M Quigley. American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. American Journal of Gastroenterology 2014; 109 doi: 10.1038/ajg.2014.187
|
| 33 |
H.P. Kapfhammer. Psychopharmakotherapeutische Ansätze bei somatoformen Störungen und funktionellen Körpersyndromen. Der Nervenarzt 2012; 83(9) doi: 10.1007/s00115-011-3446-9
|
| 34 |
Yingcong Yu, Shujuan Wu, Jianxin Li, Renye Wang, Xupei Xie, Xuefeng Yu, Jianchun Pan, Ying Xu, Liang Zheng. The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling. Metabolic Brain Disease 2015; 30(1) doi: 10.1007/s11011-014-9554-z
|
| 35 |
Jeremy R. Glissen Brown, Ava Sanayei, Samantha Proctor, Ryan Flanagan, Sarah Ballou, Paul A. Bain, Judy Nee. Examining the Nocebo Effect in Trials of Neuromodulators for Use in Disorders of Gut-Brain Interaction. American Journal of Gastroenterology 2023; 118(4) doi: 10.14309/ajg.0000000000002108
|
| 36 |
Jonathan A. Busam, Nisha Batta, Ali Rezaie, Mark Pimentel. A Systematic Review of Efficacy in Irritable Bowel Syndrome: How the Number Needed to Treat May be a Misleading Metric. American Journal of Gastroenterology 2026; 121(8) doi: 10.14309/ajg.0000000000003968
|
| 37 |
Nana Xiong, Yanping Duan, Jing Wei, Ricarda Mewes, Rainer Leonhart. Antidepressants vs. Placebo for the Treatment of Functional Gastrointestinal Disorders in Adults: A Systematic Review and Meta-Analysis. Frontiers in Psychiatry 2018; 9 doi: 10.3389/fpsyt.2018.00659
|
| 38 |
Judy Nee, Mohammed Zakari, Anthony J Lembo. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy 2015; 16(18) doi: 10.1517/14656566.2015.1101449
|
| 39 |
Yonghoon Choi, Young Hoon Youn, Seung Joo Kang, Jeong Eun Shin, Young Sin Cho, Yoon Suk Jung, Seung Yong Shin, Cheal Wung Huh, Yoo Jin Lee, Hoon Sup Koo, Kwangwoo Nam, Hong Sub Lee, Dong Hyun Kim, Ye Hyun Park, Min Cheol Kim, Hyo Yeop Song, Sung-Hoon Yoon, Sang Yeol Lee, Miyoung Choi, Moo-In Park, In-Kyung Sung. 2025 Seoul Consensus on Clinical Practice Guidelines for Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility 2025; 31(2) doi: 10.5056/jnm25007
|
| 40 |
Marzena Chrapczyńska, Agnieszka Filarecka, Piotr Przybyszewski, Emilia Przybyszewska, Julia Gatniejewska, Martyna Sienicka, Paulina Prudzic, Weronika Winiarska, Wiktoria Bełcikowska-Skowron, Aleksandra Siegmund. EFFICACY OF ANTIDEPRESSANTS IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME: A SYSTEMATIC REVIEW. International Journal of Innovative Technologies in Social Science 2026; 2(3(51)) doi: 10.31435/ijitss.3(51).2026.5878
|
| 41 |
Madhusudan Grover, Douglas A. Drossman. Centrally Acting Therapies for Irritable Bowel Syndrome. Gastroenterology Clinics of North America 2011; 40(1) doi: 10.1016/j.gtc.2010.12.003
|
| 42 |
Alexander C Ford, Eamonn M M Quigley, Brian E Lacy, Anthony J Lembo, Yuri A Saito, Lawrence R Schiller, Edy E Soffer, Brennan M R Spiegel, Paul Moayyedi. Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. American Journal of Gastroenterology 2014; 109(9) doi: 10.1038/ajg.2014.148
|
| 43 |
Yuanjun Dong, David Baumeister, Sabrina Berens, Wolfgang Eich, Jonas Tesarz. High Rates of Non-Response Across Treatment Attempts in Chronic Irritable Bowel Syndrome: Results From a Follow-Up Study in Tertiary Care. Frontiers in Psychiatry 2019; 10 doi: 10.3389/fpsyt.2019.00714
|
| 44 |
Mani Rajagopalan, Ashray Rajagopalan, Ashwin Rajagopalan. Amitriptyline in Irritable Bowel Syndrome. Current Medical Issues 2021; 19(2) doi: 10.4103/cmi.cmi_13_21
|
| 45 |
TAREK MAZZAWI, MAGDY EL-SALHY. Changes in small intestinal chromogranin A-immunoreactive cell densities in patients with irritable bowel syndrome after receiving dietary guidance. International Journal of Molecular Medicine 2016; 37(5) doi: 10.3892/ijmm.2016.2523
|
| 46 |
T Mazzawi, T Hausken, D Gundersen, M El-Salhy. Dietary guidance normalizes large intestinal endocrine cell densities in patients with irritable bowel syndrome. European Journal of Clinical Nutrition 2016; 70(2) doi: 10.1038/ejcn.2015.191
|
| 47 |
Brian E. Lacy, Mark Pimentel, Darren M. Brenner, William D. Chey, Laurie A. Keefer, Millie D. Long, Baha Moshiree. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. American Journal of Gastroenterology 2021; 116(1) doi: 10.14309/ajg.0000000000001036
|
| 48 |
Robyn Rexwinkel, Judith Zeevenhooven, Faridi S. van Etten-Jamaludin, Marc A. Benninga, Merit M. Tabbers. Side effects associated with pharmacotherapy for pediatric irritable bowel syndrome and functional abdominal pain – not otherwise specified: a systematic review. Expert Opinion on Drug Safety 2019; 18(2) doi: 10.1080/14740338.2019.1574295
|